Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study

Maurizio A. Brausi, Paolo Gontero, Vincenzo Altieri, Renzo Colombo, Ilaria Conti, Aldo Vittorio Bono

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this phase II study was to evaluate whether low-risk non-muscle-invasive bladder cancer can be ablated with intravesical gemcitabine in a marker lesion study. Patients and Methods: The study had a Simon II-stage design. Thirteen patients were to be recruited for stage I. In the event of ≥4 responses, another 30 patients were to be recruited. Patients were given gemcitabine 2,000 mg intravesically once per week for 6 weeks and the response was assessed with endoscopic, histological, and urine cytological findings. Results: Fourteen patients evaluated for efficacy completed the study; complete responses were achieved by 2 patients (14.3%), both of these patients had lesions of 1 cm may be a critical factor in accounting for the low response rate.

Original languageEnglish
Pages (from-to)470-474
Number of pages5
JournalUrologia Internationalis
Volume87
Issue number4
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Bladder tumors, non-muscle-invasive
  • Gemcitabine
  • Marker lesion

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study'. Together they form a unique fingerprint.

  • Cite this